Plantable Health completes its initial public offering


Enter Wall Street with Street Insider Premium. Claim your 1-week free trial here.

Vancouver, British Columbia – (Newsfile Corp. – December 31, 2021) – Plantable Health Inc. (“Plantable“or the”Society“), today announced the successful closing of its IPO (the”Offer“) Plantable units (“Units“) for C $ 0.40 (the”Offer price“) per Unit for gross proceeds of C $ 4.5 million. Clarus Securities Inc. (the”Agent“) acted as sole agent and bookrunner with respect to the Offer.

CEO Dr Nadja Pinnavaia said: The IPO is a critical step that allows us to expand our operations and support current and future clinical trials to clinically prove our effective solution for long-term behavior change. With plant-based nutrition, one-on-one coaching and a grassroots lifestyle platform, our mission is to end unnecessary chronic disease, bringing joy to people’s lives through healthy and supportive health. optimal well-being.

Product use

The Company expects to use the net proceeds of the Offering for sales and marketing expenses, technology development, clinical trials and for working capital purposes. The main priorities include expanding the core direct-to-consumer business by strengthening the fundamentals of e-commerce, establishing “B2B2C” partnership distribution channels following the conclusion of clinical trials, and launch of the CPG line of healthy plant-based staples, including sauces, snacks, spices and condiments designed to facilitate the Plantable lifestyle, available for sale on the website and also in stores.

Board of directors

Plantable’s board of directors, made up of 5 members, to guide and support growth, is made up of the following people:

Nadja Pinnavaia – Founder, CEO and Director: Before founding Plantable, Dr Pinnavaia was Managing Director at Goldman Sachs in London where she worked for 12 years. She also holds an undergraduate degree in chemistry from King’s College London and a doctorate. in Quantum Chemistry from St. Catharine’s College, Cambridge. She holds the certificate in culinary nutrition from the Natural Gourmet Institute.

David Kopp – Strategic Advisor and Media Director: Mr. Kopp is an experienced general manager of consumer digital health with expertise spanning strategy, product development, marketing and technology. Mr. Kopp serves on several private and not-for-profit boards, including those of HealthTap, Inc., One Care Media, LLC and From January 2016 to August 2020, Mr. Kopp was Managing Director of Healthline Media, Inc., a website and provider of health information. Mr. Kopp brings deep expertise in consumer-centric digital health businesses, particularly in growth marketing, team and culture scaling, financial planning and strategy.

Dr Jason Campagna MD, Ph.D. – Clinical Advisor and Director: Dr. Jason Campagna is a Board-certified physician and surgeon with experience in neuroscience, autoimmunology, and fatty liver disease. Dr. Campagna is currently the Medical Director of Q32 Bio Inc. Dr. Campagna was previously the Medical Director of Intercept Pharmaceuticals, Inc., a Nasdaq-listed pharmaceutical company specializing in the development of pharmacological solutions for non-viral liver disease. Dr Campagna completed his postdoctoral fellowships in neural plasticity and internal medicine at Massachusetts General Hospital in Boston. Dr Campagna brings extensive experience in clinical trials and an extensive network in major medical institutions.

Peter Hughes, B.Sc. – Senior Director: Mr. Hughes has 35 years of business experience, including senior and managerial positions in private and public companies specializing in a wide variety of industries. His experience includes corporate structuring, public and private financing, marketing, strategic planning, negotiation of agreements and management of public enterprises and operations. Mr. Hughes graduated from the University of British Columbia with a Bachelor of Science degree, completed the Canadian Securities Course at the Canadian Securities Institute, and completed the Directors and Officers Program.

Elisa Udaskin – Strategic Advisor and CPG Director: Ms. Udaskin is a seasoned brand marketer with 20 years of experience. Ms. Udaskin’s marketing career at Kraft Foods and Mondelez International has spanned traditional P&L management, innovation, customer relationship management and corporate partnerships in Canada, United States, Singapore and in the world. Ms. Udaskin obtained an MBA from the Schulich School of Business, York University in Toronto, Canada, an MBA from the Norman Paterson School of International Affairs, Carleton University, Ottawa, Canada and a BA, Policy Science at Queen’s University, Kingston, Canada.

Offer details

The Offer has been completed in accordance with the amended and updated (final) prospectus of the Company dated 23 December 2021 (the “Prospectus“) and filed with the securities commissions of the provinces of British Columbia, Alberta and Ontario, a copy of which is available under the Company’s profile on SEDAR at

Each Unit consists of one ordinary share in the capital of the Company (being a “Ordinary share“) and a half common share purchase warrant (each whole common share purchase warrant, a”To guarantee“). Each warrant entitles its holder to purchase one common share (a”Warrant share“) at an exercise price of $ 0.80 until 5:00 p.m. (Vancouver time) on December 31, 2023.

Listing of the Common Shares and the Warrants has been conditionally approved for listing on Neo Exchange Inc. (the “Neo“) under the symbol“ PLBL. ”Registration is expected to take place in mid-January and will be subject to the Company meeting all Neo requirements.

The Agent has been granted an option, which can be exercised at any time until January 30, 2022, allowing it to sell up to 1,687,500 additional units at the offer price, up to 1,687,500 shares. additional ordinary shares at a price of $ 0.395 per common share, and / or up to 843,750 additional warrants at a price of $ 0.01 per warrant, in any combination, to cover the over-allotment position of agent, if applicable, and for market stabilization purposes.

No securities regulatory authority has approved or disapproved of the contents of this press release. The securities in connection with the Offer have not been and will not be registered under the United States Securities Act of 1933, as amended (the “US Securities Act “), or the securities laws of any state of the United States and may not be offered, sold or delivered, directly or indirectly, in the United States except under an exemption from the registration requirements of the US Securities Act and This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities in any jurisdiction in which the offer or sale thereof is not not allowed.

About Plantable Health Inc.

Plantable is a clinically-supported, fundamental outcomes lifestyle change program that combines behavioral psychology, neuroscience and nutritional science to transform health and wellness. Plantable promotes healthy weight loss and improved performance, health and well-being, bringing together plant-based meals, personalized support and lifestyle tools to empower people to change their eating habits . For more information on the fundamental results of the company, please see “Summary of the Prospectus – Clinical Trials and Results” in the Prospectus.

For more information, please contact:

Dr Nadja Pinnavaia
Chief executive officer
E-mail: [email protected]

For investor inquiries, please contact:

Olenka Slawski
Corporate communication and investor relations
E-mail: [email protected]
Telephone: 778-200-4926

Caution regarding forward-looking information

Certain statements contained in this press release constitute forward-looking statements within the meaning of applicable securities laws. All statements in this press release, other than statements of historical fact, which deal with events or developments that the management of the Company expects, are forward-looking statements. More specifically, references in this press release to the listing of the Common Shares on the Neo and at the time thereof, the use of the proceeds of the offering and the mission and objectives of the Company constitute forward-looking statements. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the control of the Company, which could cause actual results and events to differ materially. of those disclosed or implied by such forward-looking statements, see “Notice to Investors – Forward-looking Information” and “Risk Factors” in the Prospectus. The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except and except as required by applicable securities laws. .

Do not distribute to US news agencies or broadcast in the United States.

To view the source version of this press release, please visit


Comments are closed.